Abstract 1722P
Background
Adherence to guidelines is linked to favorable prognosis in various cancer types. Nevertheless, the increasing complexity and sophistication of cancer drug therapy have posed challenges in identifying evidence-based treatment options. Thus, patients with cancer and local physicians are increasingly resorting to the cancer center's second opinion (SO) system for advice on treatment strategies. Integrating academic opinions from multiple physicians via SOs is expected to improve the evidence compliance rate (ECR). However, it remains unclear which cases would benefit from SOs to enhance the ECR. This study aimed to identify the factors contributing to the differences in ECR in patients with cancer.
Methods
A single-center retrospective study was conducted at the Department of Medical Oncology, National Cancer Center Hospital (Tokyo, Japan), analyzing electronic medical records of 305 patients with cancer who received SOs between January and June 2022. Two medical oncologists evaluated ECR according to the latest international standard guidelines for each cancer and classified them into two levels (Compliance: ECR is ≧50%, Non-compliance: ECR is <50%).
Results
Of 305 cases referred from 130 hospitals, 247 (81%) were female; the median age was 56 years (range: 15–85). Among them, 150 (49.2%)/152 (49.8%) were common/rare cancers, with 95 (31%) having gynecological cancers, 84 (28%) having breast cancers, and 66 (22%) having mesothelial and soft tissue cancers as major groups. After excluding cancer types for which no guidelines existed, 214 cases were eventually analyzed. Japan had a significantly higher ECR with designated core or designated hospitals for cancer genomic medicine (p=0.036). No significant relationship was found between ECR and hospital types, such as oncology, university, or urban hospitals. Moreover, no significant relationship was found between ECR and cancer types and who requested the SO.
Conclusions
This study highlights differences in ECR based on referral hospital type. The findings may aid in the appropriate allocation of medical resources between cancer centers and local hospitals as online medical care networks become more prevalent in the future.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1747P - The need for a better discussion between doctors and patients with regards to fertility preservation and vaginal rehab after anti cervical cancer treatments
Presenter: Bar Levy
Session: Poster session 23
1748P - Tackling childhood obesity epidemic on southern Europe through soft drink advertisement policies: Should oncology societies have a say?
Presenter: Konstantinos Kamposioras
Session: Poster session 23
1749P - Prevention of modifiable cancer risks in informal family caregivers of cancer patients: Implementation and evaluation of a personalised primary prevention intervention (PREV-AIDANT)
Presenter: Beatrice Fervers
Session: Poster session 23
1751P - Re-ranking cancer mortality using years of life lost
Presenter: Cecilia Radkiewicz
Session: Poster session 23
1752P - Clinical benefit of immunotherapies in advanced cancer in France: A population-based estimate from 2014 to 2021
Presenter: Isabelle Borget
Session: Poster session 23
1753P - Universal DPYD genotyping in patients with gastrointestinal malignancies: Real-world data from a single institution in Italy
Presenter: Claudia Cardone
Session: Poster session 23
1754P - Towards a next-generation sequencing/comprehensive genomic profiling value framework: Systematic review for identifying new domains and adapting a diagnostic test value framework in Europe
Presenter: Federico Augustovski
Session: Poster session 23
1755P - Carbohydrate quality index and incidence of obesity-related cancers: The Seguimiento Universidad de Navarra (SUN) project
Presenter: Maria Olmedo López-frías
Session: Poster session 23
1756P - Vizcan: A Swedish population-based study to address cancer outcomes using an interactive platform
Presenter: Anders Berglund
Session: Poster session 23